About Delinia
Delinia is a company based in Cambridge (United States) founded in 2015 was acquired by Celgene in January 2017. Delinia has raised $35 million across 1 funding round from investors including Celgene, Atlas Venture and Sofinnova Partners. Delinia operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Delinia
Delinia has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series A round of $35 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Delinia
Delinia has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Celgene, Atlas Venture and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Therapies for cancer and inflammatory diseases are developed.
|
Locked | Locked | Locked |
Investor details for Delinia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Delinia
Investment portfolio details for Delinia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Delinia
Detailed financials for Delinia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Delinia Comparisons
Peer comparison for Delinia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Delinia
Delinia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Delinia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Delinia
Complete news archive for Delinia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Delinia
Delinia was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Delinia is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Delinia is a funded company, having raised a total of $35M across 1 funding round to date.
Delinia was founded in 2015 and is based in Cambridge, United States. Operations focus on biotechnology, specifically the development of novel small molecule therapeutics for autoimmune diseases. The lead program centers on an IL12 agonist designed to potentiate and expand regulatory T cells, which play a key role in immune regulation. These efforts address pathophysiology in autoimmune conditions and related areas like cancer.
Delinia's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
Delinia has 3 investors. Key investors include Celgene, Atlas Venture, and Sofinnova Partners.